Agilent Technologies Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while ProShares UltraPro Short QQQ ETF trades at $37.58. The key difference: Agilent Technologies Inc pays a 0.69% dividend while ProShares UltraPro Short QQQ ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| A | SQQQ | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $92.95 |
52-Week Low | $110.24 | $36.31 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.4, down 3.36% today, reflecting its bearish inverse leverage against the Nasdaq-100. Technical indicators are predominantly bearish, with moving averages signaling strong sell pressure, while oscillators remain neutral. The ETF is designed for short-term tactical hedging against tech declines, not long-term holding, due to daily reset mechanics that can erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains only during sustained Nasdaq-100 downturns. Key risks include volatility decay from leverage, timing challenges, and the structural erosion documented since inception. It serves as a tactical tool for hedging, not a core investment, with success dependent on precise market timing.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →